New drug duo targets rare, aggressive eye cancer
NCT ID NCT05170334
Summary
This study is testing whether combining two drugs, binimetinib and belinostat, can help control metastatic uveal melanoma, a rare and aggressive cancer that starts in the eye. The goal is to see if this combination can shrink tumors or stop them from growing in adults whose cancer has spread. This is a Phase 2 trial, meaning researchers are evaluating how well it works and monitoring side effects in a small group of participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.